A pilot study of Galectin-3 targeting in chronic kidney fibrosis and kidney function decline Authors: Aihua Qin, Wanling Zhou, Zhen Zhang, Qiuyuan Zhou, Jing Wang, Zhenfa Wang, Ziheng Zhou, Qihao Sun, Lianjiu Su, Zhiyong Peng Published: 2026 ABSTRACT BackgroundRenal fibrosis is a key feature of chronic kidney disease (CKD), driven by persistent inflammation, immune activation, and extracellular matrix accumulation. Galectin-3, a lectin involved in immune regulation and fibrosis, has been implicated in CKD progression, but its clinical and mechanistic roles remain incompletely defined.MethodsGalectin-3 expression was assessed in human CKD cohorts and correlated with renal function. Functional studies were performed in murine adenine-induced nephropathy and unilateral ureteral obstruction (UUO) models. Genetic deletion of Galectin-3 and pharmacological inhibition using GB1107 were used to evaluate its role in renal injury. Kidney fibrosis, inflammation, and function were analyzed by histology, serum biochemistry, RNA sequencing, and molecular assays.ResultsGalectin-3 was significantly upregulated in diseased human kidneys and correlated with renal dysfunction. In mouse models, Galectin-3 was induced in injured tubular epithelial cells. Galectin-3 deficiency significantly reduced renal fibrosis, with decreased serum creatinine, blood urea nitrogen, and α-SMA expression. Transcriptomic analysis showed suppression of NF-κB signaling–related genes in knockout kidneys. Pharmacological inhibition with GB1107 similarly reduced fibrosis and improved renal function.ConclusionsGalectin-3 promotes renal fibrosis by enhancing inflammatory and pro-fibrotic signaling. Targeting Galectin-3 genetically or pharmacologically may represent a therapeutic strategy to preserve renal function and further studies are required to determine whether targeting Galectin-3 can limit CKD progression in clinical settings.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12882-026-05123-5. Introduction Chronic kidney disease (CKD) affects more than 10% of the global population and represents a growing public health crisis [1]. Characterized by progressive nephron loss, interstitial fibrosis, and impaired regenerative capacity, CKD often leads to end-stage renal disease, necessitating dialysis or transplantation [2]. Despite advances in understanding the pathophysiology of CKD, current treatment options largely aim to manage symptoms or delay progression rather than reverse established fibrosis. Thus, there is a critical need to identify molecular targets that govern the key processes driving kidney injury and fibrotic remodeling. The β-galactoside-binding lectin (galectin) family has emerged as a critical regulator of tissue homeostasis and inflammatory responses [3]. Recent studies suggest that galectin family members modulate tubular cell activation, apoptosis, and secretory programs, thereby orchestrating the crosstalk between tubular epithelium, infiltrating immune cells, and fibroblasts during CKD progression [4, 5]. Galectin-3 is a member of the β-galactoside-binding lectin family that regulates diverse biological processes including cell adhesion, immune cell activation, epithelial-mesenchymal transition, and extracellular matrix remodeling [6]. Our previous studies [7], we demonstrated that Galectin-3 is markedly upregulated during acute kidney injury. Using an integrated translational approach combining clinical observations and preclinical models, we showed that elevated Gal3 levels were associated with worse outcomes, whereas therapeutic removal or inhibition of Gal3 significantly improved survival and attenuated organ injury. These findings established Gal3 as a functionally relevant and therapeutically targetable mediator of inflammation in kidney injury. Recently, GB1107, a novel selective small-molecule inhibitor of Galectin-3, has demonstrated promising anti-fibrotic effects in models of liver and lung fibrosis [8, 9]. However, despite these encouraging findings, the efficacy and mechanistic impact of GB1107 in chronic kidney fibrosis remain largely unexplored. In this body of work, we investigate the role of Galectin-3 in the pathogenesis of kidney disease and explore its potential as a therapeutic target to mitigate fibrosis and preserve renal function. Through analysis of kidney biopsies from individuals with chronic kidney disease, we demonstrate robust Galectin-3 expression in injured renal tissue, with levels closely correlating with markers of impaired kidney function. In multiple preclinical models of kidney injury, genetic deletion of Galectin-3 markedly improved kidney function and reduced fibrosis. Furthermore, administration of GB1107, a selective small-molecule inhibitor of Galectin-3, recapitulated these protective effects by suppressing fibrotic signaling and enhancing renal epithelial recovery. These findings identify Galectin-3 as a key regulator of injury-induced inflammation and fibrosis and support the development of Galectin-3–targeted therapies as a promising approach for treating chronic kidney disease. Results Galectin-3 is robustly expressed in the diseased human kidney We investigated the association of Gal3 with human kidney disease. We first examined kidney biopsies from a cohort of individuals with chronic kidney disease (CKD) who were seen across two clinical centers in China. This cohort included 24 individuals with CKD and 5 control patients with normal kidney function (Table S1). Histological analysis revealed increased renal fibrosis and markedly elevated Gal3 expression in kidneys from CKD patients compared with healthy controls (Fig. 1A, B). Quantitative correlation analyses demonstrated that Gal3 expression was inversely associated with estimated GFR (Fig. 1C) and positively correlated with serum creatinine, BUN, and cystatin C levels (Fig. 1D–F). To further validate these findings, Nephroseq database analysis confirmed significantly higher Gal3 mRNA expression in CKD patients (Fig. 1G, H), and elevated Gal3 levels were also observed in patients with lupus nephritis and IgA nephropathy compared with healthy subjects (Fig. 1I, J). Moreover, Gal3 expression was negatively correlated with GFR in independent datasets (Fig. 1K). Together, these data demonstrate that Gal3 is markedly upregulated in human CKD and strongly correlates with disease severity and renal dysfunction. Fig. 1Galectin-3 is highly expressed in kidneys of humans with chronic kidney disease (CKD) (A) Masson trichrome staining and immunohistochemistry staining for Galectin-3 demonstrating the expression of Galectin-3 in the fibrotic region of CKD kidneys. Note minimal Galectin-3 expression in control healthy kidneys (arrowheads point to Galectin-3 expression regions; scale bars, 50 μm; representative images). (B) Quantification of Galectin-3 protein expression by H score in the control and CKD kidneys (n = 5 in control group (no kidney disease), n = 24 in CKD group; mean difference, 38.51(95% CI: 13.2–63.8), p = 0.0042). (C-F) Correlation analysis between degree of Galectin-3 protein expression (H score) in kidney with (C) GFR (n = 29) (D) serum creatinine (n = 29) (E) serum BUN (n = 29) and (F) serum cystatin C (n = 26). (G) Study design to determine degree of Galectin-3 gene expression in the kidney with metrics of kidney function from the Nephroseq database. (H-J) Renal Galectin-3 gene expression in CKD (n = 5 for healthy, and n = 27 for CKD, mean difference,0.73(95% CI: 0.175–0.129), p = 0.011). (I) lupus nephritis (n = 5 for healthy, and n = 25 for lupus nephritis, from Peterson Lupus cohort, mean difference,0.868(95% CI: 0.520–1.121), p < 0.001), (J) IgA nephropathy (n = 6 for healthy, and n = 27 for lgA nephropathy, from Reich IgA cohort, mean difference,0.586(95% CI: 0.153–1.019), p = 0.001 ). (K) Correlation between degree of Galectin-3 gene expression in kidney and GFR (n = 22, from Woroniecka Diabetes cohort). Box plots show min to max with center values set at median (H), *P < 0.05, Two-tailed Student’s t test (B, H, I, J), Pearson’s correlation analyses (two-sided) (C, D, E, F,K) Galectin-3 is highly expressed in kidneys of humans with chronic kidney disease (CKD) (A) Masson trichrome staining and immunohistochemistry staining for Galectin-3 demonstrating the expression of Galectin-3 in the fibrotic region of CKD kidneys. Note minimal Galectin-3 expression in control healthy kidneys (arrowheads point to Galectin-3 expression regions; scale bars, 50 μm; representative images). (B) Quantification of Galectin-3 protein expression by H score in the control and CKD kidneys (n = 5 in control group (no kidney disease), n = 24 in CKD group; mean difference, 38.51(95% CI: 13.2–63.8), p = 0.0042). (C-F) Correlation analysis between degree of Galectin-3 protein expression (H score) in kidney with (C) GFR (n = 29) (D) serum creatinine (n = 29) (E) serum BUN (n = 29) and (F) serum cystatin C (n = 26). (G) Study design to determine degree of Galectin-3 gene expression in the kidney with metrics of kidney function from the Nephroseq database. (H-J) Renal Galectin-3 gene expression in CKD (n = 5 for healthy, and n = 27 for CKD, mean difference,0.73(95% CI: 0.175–0.129), p = 0.011). (I) lupus nephritis (n = 5 for healthy, and n = 25 for lupus nephritis, from Peterson Lupus cohort, mean difference,0.868(95% CI: 0.520–1.121), p < 0.001), (J) IgA nephropathy (n = 6 for healthy, and n = 27 for lgA nephropathy, from Reich IgA cohort, mean difference,0.586(95% CI: 0.153–1.019), p = 0.001 ). (K) Correlation between degree of Galectin-3 gene expression in kidney and GFR (n = 22, from Woroniecka Diabetes cohort). Box plots show min to max with center values set at median (H), *P < 0.05, Two-tailed Student’s t test (B, H, I, J), Pearson’s correlation analyses (two-sided) (C, D, E, F,K) Galectin-3 is induced in experimental models of kidney injury Bulk RNA sequencing analysis revealed that Gal3 (Lgals3) expression was significantly upregulated in kidneys following adenine-induced injury, which was further confirmed by qPCR (Fig. 2A, B). Similarly, in the unilateral ureteral obstruction (UUO) model, Gal3 expression was also markedly elevated (Fig. 2C, D). Consistent with the transcriptional changes, Western blot analysis demonstrated increased GAL3 protein levels in both adenine and UUO induced kidney injury (Fig. 2E-H). Immunohistochemical staining further validated these findings, showing enhanced GAL3 expression in renal tissues from both injury models (Fig. 2I, J). Together, these results demonstrate that Gal3 is consistently upregulated at both mRNA and protein levels in multiple experimental models of kidney injury. By re-analyzing published single-cell RNA sequencing (scRNA-seq) datasets [10], we found that Gal3 expression is not static. In healthy kidneys, its signal is localized and sparse within the collecting ducts. Upon injury, however, Gal3 expression is robustly induced in virtually all tubular epithelial cells(Supplementary Fig. S1A, B). This expression pattern undergoes significant spatiotemporal evolution as the injury persists, suggesting that Gal3 may serve as a dynamic marker for tubular stress and dysfunction during the transition from acute injury to chronic disease. Fig. 2Expression of Galectin-3 after kidney injury. (A) Heatmaps showing expression patterns of collagen genes after adenine diet induced kidney injury at day 7 (n = 3). (B) qPCR results showing temporal expression of Lgals3 in injured kidneys after adenine diet at day 7(n = 5, mean difference,3.66(95% CI: 2.04–5.28), p=0.003). (C) Heatmaps showing expression patterns of collagen genes after UUO induced kidney injury at day 3 (n = 3). (D) qPCR results showing temporal expression of Lgals3 in injured kidneys after UUO at day 3 (n = 5, mean difference,8.38(95% CI: 5.78–10.98), p=0.001). (E) Western blotting and (F) quantification of Galectin-3 expression in kidneys of animals on chow and adenine diet animals at day 7. ACTIN was used as loading control, and the blot band densitometry is shown as a ratio to that in chow-fed animals (n = 3, mean difference,0.45(95% CI: 0.22–0.67), p=0.013). (G) Western blotting and (H) quantification of Galectin-3 expression in the uninjured and injured kidneys of the UUO model at day 3. ACTIN was used as reference, and the intensity of blot bands is expressed as a ratio to that in an uninjured region (n = 3, mean difference,1.11(95% CI: 0.71–1.50), p=0.007). (I) Immunohistochemistry staining for Galectin-3 in uninjured and injured kidneys of the adenine diet induced model and (J) UUO model (arrowheads point to Galectin-3 -positive cells, representative images; scale bars, 50 μm). (J). All data are shown as means ± SEM; *P < 0.05, two-tailed Student’s t test or non-parametric tests (Mann–Whitney U test) (A-H) Expression of Galectin-3 after kidney injury. (A) Heatmaps showing expression patterns of collagen genes after adenine diet induced kidney injury at day 7 (n = 3). (B) qPCR results showing temporal expression of Lgals3 in injured kidneys after adenine diet at day 7(n = 5, mean difference,3.66(95% CI: 2.04–5.28), p=0.003). (C) Heatmaps showing expression patterns of collagen genes after UUO induced kidney injury at day 3 (n = 3). (D) qPCR results showing temporal expression of Lgals3 in injured kidneys after UUO at day 3 (n = 5, mean difference,8.38(95% CI: 5.78–10.98), p=0.001). (E) Western blotting and (F) quantification of Galectin-3 expression in kidneys of animals on chow and adenine diet animals at day 7. ACTIN was used as loading control, and the blot band densitometry is shown as a ratio to that in chow-fed animals (n = 3, mean difference,0.45(95% CI: 0.22–0.67), p=0.013). (G) Western blotting and (H) quantification of Galectin-3 expression in the uninjured and injured kidneys of the UUO model at day 3. ACTIN was used as reference, and the intensity of blot bands is expressed as a ratio to that in an uninjured region (n = 3, mean difference,1.11(95% CI: 0.71–1.50), p=0.007). (I) Immunohistochemistry staining for Galectin-3 in uninjured and injured kidneys of the adenine diet induced model and (J) UUO model (arrowheads point to Galectin-3 -positive cells, representative images; scale bars, 50 μm). (J). All data are shown as means ± SEM; *P < 0.05, two-tailed Student’s t test or non-parametric tests (Mann–Whitney U test) (A-H) Galectin-3 deletion attenuates renal fibrosis and preserves kidney function after chronic kidney injury We generated Gal3 global knockout mice and validated the knockout efficiency at the protein level (Fig. 3A). In an adenine-induced chronic kidney injury model, genetic deletion of Gal3 effectively attenuated renal fibrosis. Masson’s trichrome and Picrosirius red staining showed minimal collagen deposition in chow-fed control kidneys, whereas wild-type injured mice exhibited pronounced collagen accumulation. In contrast, Gal3 knockout mice displayed markedly reduced collagen fiber deposition and a smaller extent of severe fibrosis compared with wild-type controls (Fig. 3B-E; Supplementary Fig. S2A). Consistently, renal function parameters, including serum creatinine and blood urea nitrogen (BUN), were markedly elevated in adenine-injured WT mice compared to those in the uninjured chow diet group. However, these injury-induced increases were significantly attenuated in Gal3 KO mice, which exhibited lower levels of both creatinine and BUN than their WT counterparts (Fig. 3F, G), and the accumulation of alpha-SMA-positive myofibroblasts was significantly attenuated in the kidneys of Gal3 KO mice compared to WT controls (Fig. 3H, I). To assess the extent of tubular damage, we examined the expression of Kidney Injury Molecule-1(KIM-1 ), a sensitive marker for tubular epithelial injury. The injury-induced upregulation of KIM-1 was significantly blunted in Gal3 KO mice compared to their WT counterparts(Fig. S2B, C), suggesting that Gal3 deficiency protects against epithelial cell damage. To further validate these findings, we employed the unilateral ureteral obstruction (UUO) model to induce accelerated renal fibrosis(Fig. 3J). Histological analysis revealed that while sham-operated kidneys maintained normal architecture with minimal collagen presence (Supplementary Fig. S2D), WT mice subjected to UUO developed extensive interstitial fibrosis and robust collagen deposition (Fig. 3K, L). Notably, Gal3 knockout significantly blunted these fibrotic changes, as evidenced by a marked reduction in Masson’s trichrome and Picrosirius red staining compared to WT UUO kidneys (Fig. 3K, L). These results, consistent with our observations in the adenine model, reinforce that Gal3 deficiency confers broad protection against renal fibrogenesis across different injury modalities. Fig. 3Galectin-3 deletion attenuates kidney dysfunction and fibrosis after injury. (A) Western blotting showing the deletion effect of GAL3 in the global knock out mice. (B) Schematic of experimental design for adenine diet model. (C) Histological sections of WT and Galectin-3 KO (Gal3 KO) kidneys stained with Masson trichrome and Picrosirius red staining to determine fibrosis (scale bars 50 μm, arrowheads point to fibrotic regions; representative images). (D) Quantification of fibrosis in the WT and Gal3 KO groups as a fraction of the cross-sectional surface area of the kidney (n = 10 per group, left p<0.001, right p=0.008). (E) Pie chart demonstrating the proportion of animals (%) with mild/moderate or severe fibrosis among all animals in each group (n = 10 per group). Clinical chemistry showing Serum creatinine(F)(left p<0.001, right p=0.002) and (G) BUN(left p<0.001,right p=0.005) at day 28 in chow diet(uninjured=3), injured WT and Gal3 KO animal (n = 10 per group). (H) Immunohistochemistry staining for α-SMA in WT and Gal3 KO kidneys at 28 days of adenine diet (arrowheads point to α-SMA -positive cells, representative images; scale bars, 20 μm). (I) Quantitation of α-SMA-positive cell numbers in WT and Gal3 KO kidneys at 28 days of adenine diet (n = 5). (J) Schematic of UUO animal model. (K) Masson trichrome and Picrosirius red staining to demonstrate fibrosis at 7 days after UUO (arrowheads point to fibrotic regions; scale bars, 50 μm; representative images). (L) Quantification of fibrosis in the sham (uninjured, n=3), injured WT and injured Gal3 KO animals as a fraction of the cross-sectional surface area of the kidney. (n = 8 per group, left p<0.001, right p=0.016). All data are shown as means ± SEM; *P < 0.05, two-tailed Student’s t test(I), ordinary one-way ANOVA with Tukey’s multiple comparisons test (D, F, G, L). Galectin-3 deletion attenuates kidney dysfunction and fibrosis after injury. (A) Western blotting showing the deletion effect of GAL3 in the global knock out mice. (B) Schematic of experimental design for adenine diet model. (C) Histological sections of WT and Galectin-3 KO (Gal3 KO) kidneys stained with Masson trichrome and Picrosirius red staining to determine fibrosis (scale bars 50 μm, arrowheads point to fibrotic regions; representative images). (D) Quantification of fibrosis in the WT and Gal3 KO groups as a fraction of the cross-sectional surface area of the kidney (n = 10 per group, left p<0.001, right p=0.008). (E) Pie chart demonstrating the proportion of animals (%) with mild/moderate or severe fibrosis among all animals in each group (n = 10 per group). Clinical chemistry showing Serum creatinine(F)(left p<0.001, right p=0.002) and (G) BUN(left p<0.001,right p=0.005) at day 28 in chow diet(uninjured=3), injured WT and Gal3 KO animal (n = 10 per group). (H) Immunohistochemistry staining for α-SMA in WT and Gal3 KO kidneys at 28 days of adenine diet (arrowheads point to α-SMA -positive cells, representative images; scale bars, 20 μm). (I) Quantitation of α-SMA-positive cell numbers in WT and Gal3 KO kidneys at 28 days of adenine diet (n = 5). (J) Schematic of UUO animal model. (K) Masson trichrome and Picrosirius red staining to demonstrate fibrosis at 7 days after UUO (arrowheads point to fibrotic regions; scale bars, 50 μm; representative images). (L) Quantification of fibrosis in the sham (uninjured, n=3), injured WT and injured Gal3 KO animals as a fraction of the cross-sectional surface area of the kidney. (n = 8 per group, left p<0.001, right p=0.016). All data are shown as means ± SEM; *P < 0.05, two-tailed Student’s t test(I), ordinary one-way ANOVA with Tukey’s multiple comparisons test (D, F, G, L). Pharmacological inhibition of Gal3 with the novel selective inhibitor GB1107 attenuates renal fibrosis and improves kidney function In an adenine-induced chronic kidney injury model, treatment with GB1107, a novel and selective Gal3 inhibitor (5 mg/kg, i.p. every other day) (Fig. 4A), significantly attenuated renal fibrosis in a dose independent manner(Supplementary Fig. S3A, B).Histological analysis with Masson and Picrosirius staining revealed markedly reduced interstitial collagen deposition in GB1107-treated mice compared with vehicle controls (Fig. 4B), which was confirmed by quantitative fibrosis assessment (Fig. 4C). Pathological grading further demonstrated that severe fibrosis (> 20%) occurred in 30% of vehicle-treated mice, whereas no mice in the GB1107 group developed severe fibrosis (Fig. 4D). In line with these findings, GB1107 administration improved renal function, as reflected by decreased serum creatinine and BUN levels (Fig. 4E, F). Moreover, immunohistochemistry showed a significant reduction in α-SMA–positive myofibroblasts in kidneys of GB1107-treated mice (Fig. 4G, H). Collectively, these results demonstrate that pharmacological blockade of Gal3 using the novel selective inhibitor GB1107 effectively alleviates renal fibrosis, preserves kidney function, and suppresses myofibroblast activation in chronic kidney injury. Fig. 4Galectin-3 inhibition attenuates renal dysfunction and kidney fibrosis. (A) Strategy for Galectin-3 inhibitor GB1107 administration in animals subjected adenine diet induced renal injury. (B) Masson trichrome and Picrosirius red staining to determine fibrosis of animals subjected to renal injury and treated with Veh or GB1107 (arrowheads point to fibrotic regions; scale bars, 50 μm; representative images). (C) Quantification of fibrosis in the Veh or GB1107 treated animals as a fraction of the cross-sectional surface area of the kidney (n = 8 to 10, left p<0.001, right p=0.04). (D) Pie charts demonstrating the proportion of animals (%) with mild/moderate or severe fibrosis among all animals in each group (n = 10). (E) Serum creatinine (left p<0.001,right p=0.017) and (F) BUN (left p<0.001, right p=0.018) at day 28 in the Vehicle (Veh, corn oil) or GB1107 treated animals (n = 8 to 10, chow diet control data were from figure 3). (G) Immunohistochemistry staining for α-SMA in kidneys of the Veh or GB1107 treated animals at 28 days of adenine diet (arrowheads point to α-SMA -positive cells, representative images; scale bars, 50 μm). (H) Quantitation of α-SMA-positive cell numbers in kidneys of the Veh or GB1107 treated animals at 28 days of adenine diet (n = 5, mean difference, -6.22(95% CI: -8.69 – -3.76), p=0.002). All data are shown as means ± SEM; *P < 0.05, two-tailed Student’s t test(H), ordinary one-way ANOVA with Tukey’s multiple comparisons test (C, E, F). Galectin-3 inhibition attenuates renal dysfunction and kidney fibrosis. (A) Strategy for Galectin-3 inhibitor GB1107 administration in animals subjected adenine diet induced renal injury. (B) Masson trichrome and Picrosirius red staining to determine fibrosis of animals subjected to renal injury and treated with Veh or GB1107 (arrowheads point to fibrotic regions; scale bars, 50 μm; representative images). (C) Quantification of fibrosis in the Veh or GB1107 treated animals as a fraction of the cross-sectional surface area of the kidney (n = 8 to 10, left p<0.001, right p=0.04). (D) Pie charts demonstrating the proportion of animals (%) with mild/moderate or severe fibrosis among all animals in each group (n = 10). (E) Serum creatinine (left p<0.001,right p=0.017) and (F) BUN (left p<0.001, right p=0.018) at day 28 in the Vehicle (Veh, corn oil) or GB1107 treated animals (n = 8 to 10, chow diet control data were from figure 3). (G) Immunohistochemistry staining for α-SMA in kidneys of the Veh or GB1107 treated animals at 28 days of adenine diet (arrowheads point to α-SMA -positive cells, representative images; scale bars, 50 μm). (H) Quantitation of α-SMA-positive cell numbers in kidneys of the Veh or GB1107 treated animals at 28 days of adenine diet (n = 5, mean difference, -6.22(95% CI: -8.69 – -3.76), p=0.002). All data are shown as means ± SEM; *P < 0.05, two-tailed Student’s t test(H), ordinary one-way ANOVA with Tukey’s multiple comparisons test (C, E, F). Gal3 deficiency suppresses renal inflammation by downregulating proinflammatory signaling and macrophage infiltration Principal component analysis (PCA) revealed a clear separation between WT and Gal3 KO mice, indicating marked transcriptional differences upon Gal3 deletion (Fig. 5A). Gene ontology analysis demonstrated significant downregulation of immune and inflammatory pathways in Gal3 KO mice, including interleukin-1β and interleukin-6 production, NF-κB signaling, and NLRP3 inflammasome assembly (Fig. 5B). Consistently, transcriptomic profiling revealed a broad suppression of inflammatory signaling in the absence of Gal3. Heatmap analysis showed that multiple pro-inflammatory genes, including Trim30a, Casp1, Tifab, and Nlrc3, were markedly downregulated in the kidneys of Gal3 KO mice compared to WT controls (Fig. 5C). To validate these findings, we performed RT-qPCR analysis, which confirmed that the mRNA expression levels of these inflammatory mediators were significantly attenuated upon Gal3 genetic deficiency (Supplementary Fig. S4A-D). Quantitative PCR further confirmed that Gal3 deficiency markedly reduced key downstream targets of the NF-κB pathway gene expression, such as IL-6, IL-1β, TNF-α and MCP-1 (Fig. 5D–5G). Immunohistochemistry for F4/80 showed significantly decreased macrophage infiltration in Gal3 KO kidneys compared with WT controls (Fig. 5H, I). Fig. 5Gal3 deficiency alters inflammatory signaling pathways (A) Principal components analysis (PCA) based on bulk RNA sequencing of kidneys of WT and Gal3 KO animals on adenine diet. (B) Go analysis of down-regulated genes at day 28 of adenine diet in Gal3 KO versus WT animals. (C) Heatmap demonstrate the down-regulated genes in Gal3 KO versus WT kidneys. (D-G) qPCR results showing the expression of (D) IL6(mean difference,-0.94(95% CI: -1.36 – -0.52), p = 0.003); (E) IL1b( mean difference,-0.88(95% CI: -1.38 – -0.39), p = 0.008); (F) TNF-α(mean difference,-0.86(95% CI: -1.34 – -0.39), p = 0.007) (G) MCP-1(mean difference,-0.88(95% CI: -1.31 – -0.44), p = 0.005) in kidneys of Gal3 KO versus WT animals at 28 days of adenine diet (n = 5). (H) Immunohistochemistry staining for F4/80 in WT and Gal3 KO kidneys at 28 days of adenine diet (arrowheads point to F4/80-positive cells; representative images; scale bars: 50 μm). (I) F4/80-positive cell numbers in WT and Gal3 KO kidneys at 28 days of adenine diet (n = 5, mean difference,-9.8(95% CI: -15.49 – -4.12), p = 0.008). (J) Western blotting and (K) quantification of p-P65(mean difference,-0.55(95% CI: -0.93 – -0.18), p = 0.023)and p-IκBα (mean difference,-0.28(95% CI: -0.50 – -0.06), p = 0.03)expression in the Gal3 KO and WT kidneys. ACTIN was used as reference (n = 3). All data are shown as means ± SEM; *P < 0.05, two-tailed Student’s t test or non-parametric tests (Mann–Whitney U test) (D-G, I, K). Gal3 deficiency alters inflammatory signaling pathways (A) Principal components analysis (PCA) based on bulk RNA sequencing of kidneys of WT and Gal3 KO animals on adenine diet. (B) Go analysis of down-regulated genes at day 28 of adenine diet in Gal3 KO versus WT animals. (C) Heatmap demonstrate the down-regulated genes in Gal3 KO versus WT kidneys. (D-G) qPCR results showing the expression of (D) IL6(mean difference,-0.94(95% CI: -1.36 – -0.52), p = 0.003); (E) IL1b( mean difference,-0.88(95% CI: -1.38 – -0.39), p = 0.008); (F) TNF-α(mean difference,-0.86(95% CI: -1.34 – -0.39), p = 0.007) (G) MCP-1(mean difference,-0.88(95% CI: -1.31 – -0.44), p = 0.005) in kidneys of Gal3 KO versus WT animals at 28 days of adenine diet (n = 5). (H) Immunohistochemistry staining for F4/80 in WT and Gal3 KO kidneys at 28 days of adenine diet (arrowheads point to F4/80-positive cells; representative images; scale bars: 50 μm). (I) F4/80-positive cell numbers in WT and Gal3 KO kidneys at 28 days of adenine diet (n = 5, mean difference,-9.8(95% CI: -15.49 – -4.12), p = 0.008). (J) Western blotting and (K) quantification of p-P65(mean difference,-0.55(95% CI: -0.93 – -0.18), p = 0.023)and p-IκBα (mean difference,-0.28(95% CI: -0.50 – -0.06), p = 0.03)expression in the Gal3 KO and WT kidneys. ACTIN was used as reference (n = 3). All data are shown as means ± SEM; *P < 0.05, two-tailed Student’s t test or non-parametric tests (Mann–Whitney U test) (D-G, I, K). Moreover, western blotting revealed reduced phosphorylation of P65 and IκBα in Gal3 KO mice, indicating suppressed NF-κB activation (Fig. 5J, K). Together, these results demonstrate that Gal3 deletion attenuates renal inflammation by downregulating proinflammatory cytokine expression, limiting macrophage infiltration, and inhibiting NF-κB signaling. Methods Examination of kidney specimens in human cohort All patient biospecimens and associated clinical data were collected under protocols approved by the Institutional Review Boards of Liang Ping People’s Hospital of Chongqing and the National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College. Ethical approval was obtained prior to the initiation of the study, and all procedures involving human participants were conducted in accordance with national and international ethical standards and the principles of the Declaration of Helsinki. Where applicable, the requirement for informed consent was obtained or waived by the approving institutional review boards. Paraffin-embedded human kidney tissues were obtained from the institutional biobank, and demographic characteristics along with renal function parameters were recorded (Supplementary Table 1). CKD patients were staged according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guidelines, based on estimated glomerular filtration rate (eGFR) and the underlying clinical diagnosis at enrollment. Patients were included if they had a confirmed diagnosis of CKD with available archival kidney biopsy tissue. Patients were excluded if they had acute kidney injury, active malignancy, systemic autoimmune disease, or incomplete clinical data. Control subjects were individuals with histologically normal kidney tissue and no clinical evidence of renal disease. Baseline demographic and clinical characteristics, including age, sex, eGFR, serum creatinine, serum uric acid, serum urea nitrogen, serum cystatin C and pathological diagnosis, were recorded for all participants and are summarized in Table S1. Gal3 protein expression was evaluated by immunohistochemistry (IHC). Tissue sections were pre-processed by baking, deparaffinization, rehydration, and antigen retrieval, followed by staining using the Detection IHC kit (ab64261) according to the manufacturer’s protocol. Protein expression was semi-quantitatively assessed using the H-score system. Staining intensity was graded as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). The proportion of cells at each intensity level was determined, and the H-score was calculated using the formula: H-score = (% cells at intensity 1 × 1) + (% cells at intensity 2 × 2) + (% cells at intensity 3 × 3). ImageJ software was used to perform quantitative image analysis to ensure unbiased evaluation of staining intensity and cellular distribution. To ensure the robustness of H-score assessment, all scoring was performed independently by two investigators blinded to group allocation. Inter-observer variability was assessed using the intraclass correlation coefficient (ICC), demonstrating high concordance between observers. Reproducibility was confirmed by repeated scoring of a subset of samples, yielding consistent results. Animal use and animal model The animals were kept at the vivarium, following the guidelines of the Chinese Association for Accreditation of Laboratory Animal Care and all animal experiments were approved by the Animal Care and Use Committee of Wuhan University (WP20220481). For the adenine-induced kidney injury model, healthy male mice aged 8–12 weeks were used, consistent with prior studies employing this model and to reduce variability associated with sex-specific hormonal effects [11, 12]. For the UUO model, both male and female mice aged 8 to 12 weeks were included; consistent directional effects were observed across sexes. In all experiments, littermates served as controls.These animals were drug-free, test-naive, and not involved in other experiments. Wild-type and Galectin-3 knockout mice were obtained from accredited commercial vendors (Jiangsu Jicui Biotechnology Co., Ltd.) and housed in the Zhongnan Hospital of Wuhan University animal facility. All animals were laboratory-bred and institutionally owned. To induce kidney fibrosis, WT and Gal3 KO mice were fed a 0.2% adenine diet for 28 days. For the UUO model, the procedure was carried out as previous study [12]. Mice were anesthetized with ketamine/xylazine (80 mg/kg and 20 mg/kg, respectively) via IP injection. A double ligation of the left ureter using 5 − 0 silk was performed after dorsal incision. Sham-operated mice had their ureters exposed but not ligated. Animals were randomly assigned to experimental groups using a random number generator prior to the initiation of treatment. All outcome assessments, including histological scoring, immunohistochemistry quantification, and biochemical analyses, were performed by investigators blinded to group allocation. Antibodies and drugs The following primary antibodies were used in this study: anti–Galectin-3 (Thermo Fisher Scientific, catalog no. 14-5301-82; dilution 1:200 for immunohistochemistry and 1:1000 for Western blot), anti–β-actin (Cell Signaling Technology, catalog no. 4967; dilution 1:5000 for Western blot), anti–phospho-P65 (Thermo Fisher Scientific, catalog no. MA5-15160; dilution 1:1000 for Western blot), anti–phospho-IκBα (Cell Signaling Technology, catalog no. 2859; dilution 1:1000 for Western blot), anti–α-SMA (Thermo Fisher Scientific, catalog no. 55135-1-AP; dilution 1:200 for immunohistochemistry), and anti–F4/80 (Thermo Fisher Scientific, catalog no. 14-4801-82; dilution 1:200 for immunohistochemistry). goat anti-TIM-1/KIM-1/HAVCR (Thermo Scientific, PA5-46941:1:100); Lotus Tetragonolobus Lectin (LTL) (Vector Biolabs, FL-1321-2;1:100). The selective Galectin-3 inhibitor GB1107 was purchased from GLPBIO (catalog no. GC18279). The dosing regimen (5 mg/kg, intraperitoneally, every other day) was selected based on previously published studies demonstrating its in vivo efficacy, selectivity for Galectin-3, and favorable pharmacological properties in preclinical models of fibrosis [8, 9]. Immunohistochemistry Formalin-fixed, paraffin-embedded (FFPE) kidney Sect. (4 μm) were deparaffinized in xylene (2 × 5 min) and rehydrated through a graded ethanol series (100%, 95%, 70%, 5 min each) to distilled water. Antigen retrieval was performed by heating sections in citrate buffer (10 mM, pH 6.0) or EDTA buffer (1 mM, pH 9.0) in a microwave or pressure cooker for 10–20 min, then cooling to room temperature. Endogenous peroxidase activity was quenched by incubating slides in 3% hydrogen peroxide in methanol for 10 min. Sections were blocked with 5% normal serum (matched to the secondary antibody host) in PBS containing 1% bovine serum albumin (BSA) for 30 min at room temperature to reduce nonspecific binding. Primary antibodies (diluted in 1% BSA/PBS) were applied and incubated overnight at 4 °C (typical dilutions 1:100–1:500; optimize per antibody). After three washes in PBS (5 min each), sections were incubated with an HRP-conjugated secondary antibody for 1 h at room temperature. Immunoreactivity was visualized using 3,3′-diaminobenzidine (DAB) substrate according to the manufacturer’s instructions (usually 1–5 min), producing a brown reaction product. Slides were rinsed in water, counterstained with hematoxylin (30 s–2 min), dehydrated through graded ethanol and xylene, and cover slipped with a permanent mounting medium. Negative controls lacking primary antibody and known-positive tissue controls were included in each run. For fluorescent IHC, use fluorophore-conjugated secondary antibodies, protect slides from light, and mount with an antifade medium containing DAPI. Imaging was performed on a Nikon Eclipse Ti2 confocal or equivalent microscope. qPCR For qPCR, injured and uninjured kidney tissue was harvested at different times after injury. RNA was extracted with the RNeasy Mini kit (QIAGEN, 74104), cDNA was synthesized using the iScript cDNA Synthesis Kit (Bio-Rad, 1708890). Quantitative real-time PCR was performed using SYBR Green Supermix and the iCycler Real-time PCR Detection System (Bio-Rad). Primer use: mouse Lgals3: forward primer AGACAGCTTTTCGCTTAACGA; reverse primer GGGTAGGCACTAGGAGGAGC. Mouse IL-6: forward primer TAGTCCTTCCTACCCCAATTTCC; reverse primer TTGGTCCTTAGCCACTCCTTC. Mouse IL-1b:forward primer GCAACTGTTCCTGAACTCAACT; reverse primer ATCTTTTGGGGTCCGTCAACT. Mouse MCP-1: Forward Primer ATCCACGGCATACTATCAACATC; reverse primer CAAGGCTCACCATCATCGTAG. mouse Trim30a: forward 5’-AGTGGGGAAAGCTCCTCTGT-3’, reverse 5’-GAACCGGTTCTTCGCTGTCT-3’; mouse Nlrc3: forward 5’-CCGGCATCATCTTCAGCAGT-3’, reverse 5’-AAGGGTCTCAGGCTTGGTGT-3’; mouse Tifab: forward 5’-GGTCCTTTGAGCAGCACAGA-3’, reverse 5’-TGTTTCCCGAGTTTCCAGCC-3’; mouse Casp1: forward 5’-GCCCAAGGTGATCATTATTCAG-3’, reverse 5’-GGGCAAGACGTGTACGAGT-3’; and mouse Gapdh: forward 5’-AGGTCGGTGTGAACGGATTTG-3’, reverse 5’-GGGGTCGTTGATGGCAACA-3’. Western blotting Kidney tissues were lysed and centrifuged, the supernatant was used to determine total protein concentration with the Pierce BCA assay (Thermo Fisher, 23235). Equal amounts of total protein were subjected to SDS-PAGE gels and transferred onto polyvinylidene fluoride (PVDF) membranes (Merck Millipore, Germany). Membranes were blocked with 5% milk and then incubated with primary antibodies.Specific protein bands were visualized by exposure machine (GE, Amersham ImageQuant 800,) using enhanced-chemiluminescent (ECL) substrate (Thermofisher, 34580) and quantitatively processed with Image J software. Blood biochemical parameters and kidney histology Blood samples were collected by cardiac puncture under deep anesthesia with isoflurane after complete loss of reflexes. Following blood collection, mice were euthanized by isoflurane overdose followed by cervical dislocation to ensure death, in accordance with IACUC guidelines. All procedures were performed in accordance with institutional guidelines and were approved by the Institutional Animal Care and Use Committee (IACUC). Serum creatinine and blood urea nitrogen (BUN) levels were determined using commercially available assay kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer’s protocols. Kidneys were harvested under anesthesia followed by fixation in 4%formaldehyde in PBS at 4 °C for 24 h to 36 h and subsequently subjected to paraffin-embedding (FFPE) according to standard methodologies. For immunostaining, paraffin sections underwent pre-treatment processes including baking, deparaffinization, rehydration, and antigen retrieval. The tissue sections were blocked in 10% species-specific normal serum in 1% BSA/PBS for 1 h, and primary antibodies diluted in 1% BSA/PBS at 4 ℃ overnight. Secondary antibodies were diluted in PBS and incubated with sections for 1 h. Samples were counterstained with DAPI (1 mg/mL, Invitrogen, D3571) and mounted with SlowFade Gold Antifade reagent (Invitrogen, S36936). Images were taken using Nikon Eclipse Ti2 confocal microscopy (Nikon, USA) and analyzed in NIS Element AR software (Nikon). For Masson Trichrome and Picro Sirius Red staining, sections were stained using Masson Trichrome Stain kit (Thermo Scientific, 87019) and Picro Sirius Red staining Kit(ab150681). For Fibrosis tissue area was calculated according to the collagen area. Fibrosis severity was graded according to the proportion of fibrotic area: samples with < 10% fibrotic area were defined as mild fibrosis, 10–20% as moderate fibrosis, and > 20% as severe fibrosis. Nephroseq database analysis Publicly available kidney gene expression datasets were accessed through the Nephroseq database (https://www.nephroseq.org). Datasets were selected based on the availability of annotated clinical metadata, a confirmed kidney disease diagnosis, and sufficient sample size to permit meaningful comparison. Gene expression data were analyzed using the normalized values provided within each dataset, following the original processing pipelines deposited by the respective study authors.All analyses were performed independently within each dataset. Bulk-RNA sequencing For bulk RNA sequencing, injured and uninjured kidney tissues were collected at various time points after injury. Total RNA was extracted with the RNeasy Mini kit (QIAGEN) and used to generate RNA-Seq libraries, which were sequenced on an Illumina HiSeq 4000 platform (single-end, 65 bp). The quality of sequencing reads was evaluated by FastQC. All RNA-seq samples were processed in a single experimental batch using identical library preparation and sequencing workflows; therefore, no batch correction was required. The transcript quantification was performed by Salmonusing mouse reference transcriptome (GRCm39). The transcript-level quantification of estimated counts, length, and abundance from Salmon were imported into DESeq2 using tximport package. DESeq2 uses a negative binomial model to model the variability of raw counts and Wald test to estimate differences between the conditions. DEseq function was performed with default setting. The transformed count data were used for PCA visualization. Using the results function, we selected genes with a adjusted p value < 0.05 and logFC > 1 or <-1 as differentially expressed genes (DEG). The cluster Profiler was used for GO pathway, GSEA analysis and visualization. Statistical analysis All data are presented as mean ± standard error of the mean (SEM), and the value of n represents biological replicates. Statistical analyses were performed using GraphPad Prism (version 8). For comparisons between two groups, Student’s t-test was used when normality could be assumed; for experiments with small sample sizes (n ≤ 5), normality assumptions were reassessed, and non-parametric tests (Mann–Whitney U test) were applied where appropriate. For comparisons among multiple groups, one-way ANOVA followed by Tukey’s multiple comparison test was used. For categorical outcomes, including fibrosis severity grading, Fisher’s exact test was used, and corresponding p-values are reported. For qPCR panel analyses involving multiple genes, false discovery rate (FDR) correction using the Benjamini–Hochberg method was applied to control for multiple comparisons. For correlation analyses involving multiple pairwise tests, statistical significance was interpreted in the context of multiple testing, and FDR-adjusted p-values were reported where applicable. Correlation analyses were performed using Pearson or Spearman correlation coefficients to assess the relationships between variables, with the choice of method determined by data distribution. Sample sizes were determined based on prior experience with these experimental models and effect sizes reported in the published literature. For experiments with small sample sizes (n ≤ 5), these were designed as mechanistic or proof-of-concept analyses, and findings were supported by concordant results across independent experimental cohorts and complementary assays. Statistical significance was defined as FDR-adjusted p < 0.05 or unadjusted p < 0.05 as indicated in the figure legends. Exact p-values are reported throughout unless p < 0.001. Specific tests are mentioned in the figure legends. Discussion Renal fibrosis is the final common pathway of various chronic kidney injuries and remains a major barrier to functional recovery of the kidney once fibrosis is established. In this study, we identify Galectin-3 as a critical mediator of kidney fibrotic remodeling, supported by both human biopsy data and mechanistic evidence from murine models. We demonstrate that Galectin-3 is markedly upregulated in diseased renal tissue, correlating strongly with reduced GFR and increased levels of serum creatinine, BUN, and cystatin C. These findings position Galectin-3 not only as a biomarker of renal injury but also as a potential driver of disease progression. Galectin-3 (Gal3) is a key regulator of inflammation and fibrosis and has been increasingly recognized as a clinically relevant biomarker in kidney and cardiovascular diseases. Elevated circulating Gal3 levels have been associated with chronic kidney disease (CKD) progression, heart failure severity, and poor patient outcomes, supporting its utility for early prediction and risk stratification [13, 14]. In our study, we observed that Gal3 expression in CKD patients correlates closely with renal dysfunction, suggesting its potential as a marker of chronic kidney injury. Studies in liver and lung fibrosis have linked Gal3 to macrophage activation, extracellular matrix accumulation, and adverse tissue remodeling [15, 16]. We found that genetic deletion of Galectin-3 attenuated renal fibrosis in mouse models, supporting a functional role for Galectin-3 in fibrotic progression under experimental conditions. These findings suggest that Galectin-3 may be involved in pathways relevant to chronic kidney disease, although their therapeutic implications require further validation. Mechanistically, our bulk transcriptomics and targeted assays implicate NF-κB as a major downstream axis through which Galectin-3 exerts proinflammatory and profibrotic effects However, definitive assessment of the relationship between Galectin-3 and NF-κB will require functional experiments, including NF-κB pathway inhibition. Loss of Galectin-3 suppressed NF-κB–regulated cytokines (IL-6, IL-1β) and chemokines (MCP-1/CCL2), and was associated with reduced F4/80⁺ macrophage infiltration. Galectin-3, as a β-galactoside-binding lectin, may facilitate the stabilization of glycosylated receptors such as TLR4 and TNF receptor superfamily members on epithelial cells [17, 18], thereby prolonging receptor clustering and enhancing NF-κB pathway activation. While Gal3 is known to be expressed in various inflammatory cells and can modulate immune activation [19], our spatiotemporal analysis of single-cell transcriptomics in both mouse and human datasets suggests that its pathological burden in CKD may be epithelial-driven although future studies using lineage tracing and/or conditional knockout models will be required to rigorously validate this conclusion. This robust induction in tubular epithelial cells, coupled with the relatively low expression levels detected in infiltrating immune cells and podocytes, underscores the significance of tubular-derived Gal3 in the process of kidney injury. Importantly, beyond genetic deletion, we showed that pharmacological inhibition of Galectin-3 using GB1107 recapitulates the protective effects seen in knockout models. GB1107-treated animals displayed significantly improved renal function, reduced collagen deposition, and suppressed myofibroblast activation. Unlike broad-spectrum anti-inflammatory agents, GB1107 selectively targets the glycan-binding pocket of Galectin-3 [9], thereby disrupting its ability to scaffold glycosylated receptors and sustain NF-κB–driven inflammatory signaling. These results indicate that pharmacological inhibition of Galectin-3 with GB1107 modulates fibrotic and inflammatory responses in preclinical models. Our study mainly emphasizes the antifibrotic efficacy of Gal3 inhibition in the kidney, and the upstream regulatory mechanisms and downstream signaling networks of Gal3 were not comprehensively investigated. Whether Galectin-3 inhibition promotes true tissue regeneration or merely halts fibrotic progression warrants further investigation using lineage tracing and single-cell transcriptomics. We acknowledge several limitations of the human cohort analyses. First, the relatively small sample size precluded multivariable adjustment for potential confounders such as age, sex, disease etiology, and comorbidities, and these analyses should therefore be interpreted as descriptive and associative rather than causal. Formal power calculations were not conducted, and the study was not designed to provide definitive effect estimates. Moreover, while pharmacologic inhibition of Galectin-3 showed consistent biological effects, further studies are required to fully establish dose–response relationships, target engagement, and therapeutic specificity. Second, in the Nephroseq reanalysis, the number of healthy control samples was substantially smaller than that of CKD cohorts, which may further limit statistical power and introduce potential bias. Future studies with larger, well-annotated cohorts will be necessary to perform robust multivariable adjustment and validate these associations. In conclusion, this study implicates Galectin-3 in the coordination of inflammatory and pro-fibrotic signaling during renal injury and fibrosis. Our experimental data suggest that Galectin-3 links epithelial injury with immune activation and fibroblast responses in preclinical models. Although pharmacological inhibition of Galectin-3 with GB1107 attenuated fibrotic phenotypes in these settings, its clinical utility and impact on current treatment strategies will require rigorous evaluation in future translational and clinical studies. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2 Supplementary Material 3 Supplementary Material 3